Development of fish allergy immunotherapy using hybrid peptides

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K21458
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Collagenous pathology/Allergology; Dermatology
• Research Institution: Fujita Health University
• Principal Investigator: Shimojo Naoshi 藤田医科大学, 医学部, 客員准教授 (70410751)
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: アレルゲン免疫療法 / 低アレルゲン化 / 魚アレルギー

Outline of Final Research Achievements

In this study, it was carried out mainly by constructing animal model, protein and peptide experiment which was necessary for the development of the immunotherapeutic agent which suppresses allergic symptoms as much as possible. As the result, the animal model which is similar to the pathophysiologic mechanism of the human was constructed, and various tests which became an index of the inhibition research for fish allergy were almost established. Although peptide synthesis could not be performed in this study, nine fish recombinant proteins were successfully generated and their reactivity to mouse IgE was confirmed. Thus, we succeeded in establishing a test system for conducting an allergy suppression test, and in the future, we will synthesize peptides derived from identified antigens and create an optimal immunotherapeutic agent.

Free Research Field

食物アレルギー

Academic Significance and Societal Importance of the Research Achievements

アレルギー症状の誘発を極力抑え、かつ効率的な寛容状態へ誘導させる免疫療法を確立させることにより、患者のリスク低減や患者QOL向上につながる。また、免疫療法を実施する医療従事者への医療現場での負担軽減にも寄与すると考える。